ImmunityBio is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer (NK) cell to treat cancer and viral infectious diseases. NK cells are the body's first line of defense due to their innate ability to seek and destroy abnormal cells, such as cancer or virally infected cells, without prior exposure or activation by other support molecules, required to train and activate adaptive immune cells such as T-Cells. Co. holds the right to commercialize activated NK cells, a commercially viable natural killer cell line, and a range of genetically modified derivatives capable of killing cancer and virally infected cells. The IBRX stock yearly return is shown above.
The yearly return on the IBRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the IBRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|